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Background: Small molecule effects can be represented by active signaling pathways within functional networks.
Identifying these can help to design new strategies to utilize known small molecules, e.g. to trigger specific cellular
transformations or to reposition known drugs.
Results: We developed CellFateScout that uses the method of Latent Variables to turn differential high-throughput
expression data and a functional network into a list of active signaling pathways. Applying it to Connectivity Map
data, i.e., differential expression data describing small molecule effects, we then generated a Human Small Molecule
Mechanisms Database. Finally, using a list of active signaling pathways as query, a similarity search can identify small
molecules from the database that may trigger these pathways. We validated our approach systematically, using
expression data of small molecule perturbations, yielding better predictions than popular bioinformatics tools.
Conclusions: CellFateScout can be used to select small molecules for their desired effects. The CellFateScout Cytoscape
plugin, a tutorial and the Human Small Molecule Mechanisms Database are available at https://sourceforge.net/projects/
cellfatescout/ under LGPLv2 license.
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Searching for chemical substances (often called small
molecules) that trigger a desired effect in cells is frequently
done in the laboratories of pharma and biotech companies.
Computational work enables a speed-up of this search,
based on three ingredients: (1) high-throughput data
describing the desired effect of turning cells of type A
into cells of type B, e.g. by measuring gene or protein
amounts in diseased cells and in healthy cells, (2) high-
throughput data measuring how such amounts change
in cells if small molecules are applied, and (3) know-
ledge about possibly relevant cellular signaling pathways.
Our procedure contributes towards the improvement of
methods for finding small molecules that may turn, e.g.,
diseased cells into healthy cells, based on such data. The* Correspondence: fuellen@uni-rostock.de
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reproduction in any medium, provided the orsuggested small molecules can then be directly tested with
a higher chance of success.
Background
Over the last decades, drug discovery and development
was the focus of many studies. Although advances were
made, traditional drug development is still time-consuming,
risky and costly [1]. An alternative drug discovery strategy,
called repositioning, is to explore known drugs for new
applications [2]. Often, repositioning is done using mech-
anistic knowledge of the targets and the pathways affected
by the drug (small molecule), or by comparing cellular or
clinical phenotypes. These approaches can be improved
by computational analyses. They can aid in generating,
evaluating and prioritizing data for many small mole-
cules, targets, pathways and phenotypes simultaneously
[3]. Thus, there is a rising interest in bioinformatics tools
elucidating new areas of application for known small mol-
ecules, which modify, in one way or another, the state of
cells, organs and organisms. Further, the repositioningtral Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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bioinformatics-based tools for repositioning can equally
well be used to find small molecules that trigger desired
cell (de-)differentiation or transdifferentiation events, such
as the induction of pluripotency, endodermal or neural
fate [4,5]. Data from this application area of repositioning
will be used to demonstrate and validate our work, motiv-
ating the name of the tool we developed.
Various network-based methods have been developed
for identifying gene expression signatures, i.e., sets of
genes combined with a pattern of their expression that
is typical for some cellular state. These methods have
been applied e.g. to the prediction of response to drug
treatment [6]. Bioinformatics network analysis of high-
throughput data sets offers an opportunity for data inte-
gration considering biological complexity and multilevel
connectivity [7], on the network, subnetwork, pathway
or single gene/protein interaction level. Some of these
network-based methods have been released as bioinfor-
matics tools. A pioneer method that searches for so-called
active subnetworks through a permutation-based algorithm
is presented in [8]. It combines differential expression based
p-values with a given network and is implemented by the
jActiveModules Cytoscape plugin. This tool is dependent
on a method that provides p-values for the change in gene
expression, e.g. a t-test. It scores subnetworks by comparing
two (or more) conditions, e.g. case and control. The score
of a subnetwork is calculated by aggregating the z-scores
of the individual genes based on the p-values; random
resampling is used to estimate whether the subnetwork
score is higher than expected by chance. To find the
highest-scoring subnetwork in a full network, jActive-
Modules uses a heuristic approach based on simulated
annealing. jActiveModules utilizes the network struc-
ture to find a connected set of genes, however it is not
taking into account whether the considered network re-
gion is highly connected. Also, it does not consider the
directionality of links. While jActiveModules is perform-
ing subnetwork evaluation based on calculating genewise
p-values, another network based bioinformatics tool,
KeyPathwayMiner, requires the explicit selection of sig-
nificantly differentially expressed genes. Based on this
information, KeyPathwayMiner finds highly connected
subnetworks where most genes are expressed in most sam-
ples [9]. This bioinformatics tool, just as jActiveModules,
depends on another method, which classifies genes as
significantly differentially expressed. Like jActiveModules,
KeyPathwayMiner is also able to compare two or more
conditions. The method considers the connectivity in a
network, assuming that active regions consist of differ-
entially expressed genes that are highly connected. How-
ever, link directionality is not considered either. According
to [9], KeyPathwayMiner outcompeted CUSP [10],
GiGA [11], jActiveModules and a standard t-test. Anotherbioinformatics tool that is employed for unveiling network
activity is ExprEssence [12]. Here, the authors developed a
method inspired by the law of mass action that highlights
interactions (links) for which the two connected genes/
proteins feature a large amount of coordinated change.
This method takes link directionality into account; every
link can be specified as an inhibition, stimulation or inter-
action between two genes. ExprEssence is focused on find-
ing single links connecting genes with coordinated change
of expression, thus, an entire subnetwork is highlighted
only as appropriate, that is, only if all links show high ex-
pression change. ExprEssence does not consider issues of
statistical significance; it just returns a list of links, sorted
by a score reflecting differential change. All mentioned
tools, jActiveModules, KeyPathwayMiner and ExprEssence,
are based on easy to interpret models that are computa-
tionally fast. Users of these approaches usually assume that
the signaling between proteins is reflected by gene expres-
sion change.
In this study, we developed a network-based bioinfor-
matics tool and Cytoscape plugin called CellFateScout
that explores an expression signature in a network con-
text and then suggests the repositioning of small mole-
cules to emulate the given signature. The workflow of
our study is illustrated in Figure 1. In our approach, a
signature is defined by a set of pathways in the form of
linear chains, representing a set of active signaling path-
ways in the network. For finding such a signature, we
utilize the flexibility of the Latent Variable Model frame-
work [13,14]. This flexibility allowed the authors of [15]
to use latent variables for biological network analysis in
a different context. We demonstrate that the Latent
Variable Model approach is able to predict small mol-
ecule effects in terms of expression signatures better
than other bioinformatics tools. We employ genome-wide
expression profiles of cells treated with small molecules
from the Connectivity Map [16]. We use CellFateScout to
find the active signaling pathways based on the expression
signatures of these small molecules, and store them in the
Human Small Molecule Mechanisms Database (SMMD).
Having a tool that can reveal active signaling pathways
from a high throughput expression experiment, we can
finally identify small molecules from the SMMD that
may emulate the signaling mechanisms underlying that
experiment.Results and discussion
In this study, we introduce a bioinformatics tool called
CellFateScout that is implemented as a Cytoscape plugin.
Using the method of Latent Variables [13,14], our tool
reveals active signaling pathways based on differential
expression data from two conditions, interpreted in the
context of a functional network.
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We performed a validation of our method against four
other bioinformatics tools answering the question: how
far away from the known targets of the small molecules
are the active pathways we find? In [14], the perform-
ance of the Latent Variable Model is illustrated by a set
of simulation studies and an analysis of gene expression
data for environmental stress response in yeast. Here,
we perform a detailed and systematic analysis of their
approach as implemented by our plugin, including a
comparison of CellFateScout with other available and
well-known bioinformatics tools, representing distinct
methods for elucidating pathway information from
expression data. From the tools mentioned in the
introduction, we compare to jActiveModules, KeyPathway-
Miner and ExprEssence. Often, changes in expression
levels on a genome-wide scale are still assessed on an in-
dividual basis, essentially resulting in long lists of genes
that are found to have significant change, and sometimes
the simplest approaches (as well as random guessing of
results) may outperform complicated approaches. There-
fore, we also compare to the limma [17] package from
Bioconductor [18], simply selecting the most differentially
expressed genes as pathway elements activated by a small
molecule. CellFateScout and the other tools were sub-
jected to the same validation protocol and the resulting
p-values were computed in the same manner. This allowed
a systematic and comprehensive comparison of all tools.
The workflow of our validation is illustrated in Figure 1A.
The selection of small molecules, corresponding gene ex-
pression data and functional networks as well as the defin-
ition of target neighborhoods and of the distance between
the known targets and the gene sets found by a bioinfor-
matics method are described in ‘Methods’.
Based on our validation protocol, we obtained p-values
describing the closeness of the known targets of selected
small molecules to the active subnetworks/pathways
estimated by bioinformatics. For better visualization, we
turned the p-values into histogram bar heights, where large
height corresponds to small p-values (indicating closeness).
The resulting histograms are shown in Figures 2 and 3
for the mouse and in Figures 4 and 5 for the human
validation data. (Details of the validation data can be found
in Additional file 1 for mouse and in Additional file 2
for human). We notice in Figures 2 and 4, which are
based on the STRING functional network [19], that
CellFateScout obtains the best score in 8 out of 11 cases
for mouse and 6 out of 10 cases for human, respectively.
However, employing iRefIndex [20] to construct the
functional networks, we cannot find differences in re-
sult quality for any of the bioinformatics tools. Here,
CellFateScout and ExprEssence are shown to be equally
good, but only better to KeyPathwayMiner and jActive-
Modules by one or two cases. Also, randomization-basedp-values do not show a significant difference for any
tool in more than half of the cases, indicating a lower
detection rate for small molecule effects in iRefIndex
networks, as compared to STRING networks.
To study further the impact of the choice of the
network construction source in our validation, we com-
pared p-values for both sources and both species. Since
samples are dependent and only the network construction
methodology is varying, we used a one-sided paired t-test.
For mouse, the mean of the differences of the p-values
is −0.1938 between STRING and iRefIndex, and based
on a one-sided paired t-test this difference is signifi-
cantly smaller than 0 with p-value = 0.002. Thus, using
STRING we observe an improvement of results; the
active subnetworks/pathways are closer to the targets,
and this is supported by smaller p-values. Based on the
validation weighting function (see Methods), targets and
genes directly connected to these targets obtain high
weights and have a pivotal impact on the weighted mean
distance. We noticed that on average, incoming links to
these pivotal genes comprise 15.14% of all links in a
STRING network, but only 8.56% in an iRefIndex net-
work. In other words, given a more interconnected
neighborhood close to the small molecule targets in
STRING networks, more differentially expressed genes
are connected to each other. Thus, in case of STRING,
bioinformatics tools are able to report more links (being
part of subnetworks or pathways) that connect genes in
a neighborhood close to a small molecule target. For
human, the mean of the differences of the p-values
is -0.05209, which is not significantly smaller than 0
(one-side paired t-test, p-value = 0.187). Our findings
confirm that in the context of our studies, STRING
enables superior results than iRefIndex.
In summary, we find that CellFateScout together with
STRING has the most success to discover pathways that
are close to a small molecule’s known targets. Second best
tool is ExprEssence, which is better than KeyPathwayMiner
and jActiveModules by one or two cases. Our validation
cannot confirm results from [9], where KeyPathwayMiner
outcompeted jActiveModules. Limma, the gene-wise
approach for identifying differentially expressed genes,
has a best score in only one case study. This indicates
that genes exhibiting highest change in expression do
not have to be close to the targets of the small molecule
under consideration. We also noticed that KeyPathway-
Miner in 11 out of 20 cases in mouse and 9 out of 19
cases in human returns as output large subnetworks
comprising of more than 20% of the genes from the an-
alyzed network (see Additional file 1). Even when the
output includes targets or genes close to targets, this
indicates high recall at the expense of low precision,
which can hamper clear and straightforward interpret-
ation. In summary, our systematic validation suggests
Figure 1 (See legend on next page.)
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Figure 1 CellFateScout study workflow. A) Validation pipeline. For each small molecule considered, we collected publicly available differential
gene expression data describing its effect, information about its targets in STITCH, and a functional network. Using CellFateScout and other
bioinformatics tools, we predicted the signaling pathways that it activates and evaluated how much closer these are to its known targets in the
network, compared to randomly generated pathways. B) We combined gene expression data taken from the Connectivity Map project,
information about small molecules targets from STITCH and functional networks from STRING to perform a systematic search with CellFateScout
for active pathways triggered by small molecules and stored them in the Small Molecule Mechanisms Database. C) As input for active signaling
pathway discovery, a functional network and a differential expression data set featuring two conditions A and B are needed. The discovered
active pathways are shown in a Cytoscape network view and used to query the Small Molecule Mechanisms Database for matching signaling
pathways triggered by small molecules. The resulting small molecules are then listed in a result table and we can highlight edges and nodes that
are shared between the active pathways found by CellFateScout and the active pathways triggered by small molecules.
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pathway identification.
Small molecule mechanisms database
Using CellFateScout together with expression data taken
from the Connectivity Map project, small molecule targets
from STITCH and functional networks from STRING,
we performed a systematic search for active pathways
triggered by small molecules and stored them in a Small
Molecule Mechanisms Database as illustrated in Figure 1B.















Figure 2 CellFateScout validation using mouse data and STRING netw
small molecules of Table 1, for 5 different bioinformatics tools. p-values ind
perform in terms of their proximity to the known small molecule targets, com
bars indicate superior performance, i.e., the pathways found by the bioinformqueried, given a list of active signaling pathways derived
from differential gene expression data, returning a set of
small molecules that may trigger the same active path-
ways. A detailed description of the input, the output,
the usage of our tool and of our methodology can be
found in ‘Methods’.
More specifically, we developed a Small Molecule Mech-
anisms Database (SMMD) comprising 818 small molecule
records (see below) associated with the mechanisms
triggered by them. These mechanisms, presented as ac-
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pared to randomly generated pathways of same size. Higher histogram





















Figure 3 CellFateScout validation using mouse data and iRefIndex networks. The histograms of –log10 transformed p-values are shown for
9 small molecules of Table 1, for 5 different bioinformatics tools. See the Figure 2 legend for details.
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effects as found by our plugin. Right now the database
features only human mechanisms, however this can be
extended to other species.
To construct the SMMD, we used the Connectivity
Map (CMap, [16]) database, a collection of microarrays,
where drug effects in human cells are measured in a
large-scale, systematic way, focusing on expression pro-
files of the response of cell lines to 1309 small mole-
cules. Specifically, the small molecules were investigated
in various doses in 4 different cell lines (breast epithelial
adenocarcinoma MCF7, prostate adenocarcinoma epithe-
lial PC3, nonepithelial promyelocytic leukemia HL60 and
malignant melanoma SKMEL5) by hybridization on 3
Affymetrix microarray platforms (HG-U133A, HT_HG-
U133A, HT_HG-U133A_EA). Here, a record is a unique
combination of a small molecule, its concentration, the
cell line and the platform used. We ignore all records for
which there are no microarray replicates in CMap (for
case and control) or no targets in STITCH [21] connected
to the small molecule with confidence of at least 0.9. All
SMMD records are documented in Additional file 3.
Microarray data is processed for every platform separately.
We normalized all raw data from CMap (over 7000 arrays)with the aroma.affymetrix [22] R package for analyzing
large Affymetrix data sets. In the CMap project, data were
collected in multiple batches, each defined as a set of cases
and controls performed together. For some of the data-
base records, microarrays are taken from more than
one batch. In order to remove batch-to-batch technical
variation we follow [23] and apply ComBat [24]. Then,
every SMMD record is analyzed individually. We con-
struct networks of the top 2000 differentially expressed
genes selected by limma. In agreement with conclu-
sions from our validation effort, we employ STRING
(but not iRefIndex) for network construction. In 73.58%
cases, the known targets of a small molecule are not in-
cluded in the network based on differential expression.
Therefore, to improve the comprehensiveness of the
database, we added curated knowledge about targets of
small molecules from STITCH. More specifically, we
added the known small molecule targets to the network
together with neighborhoods of size large enough to
connect these targets to the rest of the network. Finally,
we run CellFateScout over all pathways (chains) in the
network starting with a small molecule target gene, and
for each small molecule, the 100 most active pathways





















Figure 4 CellFateScout validation using human data and STRING networks. The histograms of -log10 transformed p-values are shown for 10
small molecules of Table 2, for 5 different bioinformatics tools. See the Figure 2 legend for details.
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ented database management system, and stored in one
file. The user can view the SMMD file content with the
ObjectDB Explorer tool, which is part of the ObjectDB
project. The SMMD is available as Additional file 4 and
also at https://sourceforge.net/projects/cellfatescout/.
Using CellFateScout, we can discover active signaling
pathways. Having a list of these, we can perform an
automated query in the Small Molecule Mechanisms
Database to identify records of small molecules that may
trigger the same pathway activity. For each active pathway,
we thus search for SMMD records featuring database
pathways with a low p-value and with matching genes
from the active pathway. For an active pathway (AP) and a
database pathway (DP) pair, we define a similarity score:
score AP;DPð Þ ¼ overlap AP;DPð Þ
pvalueAP þ pvalueDP ;
where the overlap in the numerator is defined as follows,
overlap AP;DPð Þ ¼ number of genes in AP and in DP
number of genes in AP
:We sort the query result based on the similarity score.
Then, we collect the 100 best small molecule records with
their respective database pathways and present these
in CellFateScout.
CellFateScout assumptions, application example,
strengths and weaknesses
In contrast to bioinformatics tools designed to focus on
finding pathways or connected subnetworks composed
of genes that are significantly differentially expressed,
CellFateScout uses the Latent Variable Model and con-
siders the joint expression level of all genes in a pathway
under investigation and thus takes into account the
expression level of all genes in the entire network, and
their interactions. Therefore, genes that have only few
connections and that are not exhibiting significant expres-
sion change may still be considered components of active
pathways. In such cases, signaling is done through e.g.
phosphorylation of the protein product. This is an im-
portant aspect to consider when analyzing small molecule
responses. Accordingly, there is evidence in drug target
studies that significantly differential expression analysis
is only partially effective in detecting target genes [26]





















Figure 5 CellFateScout validation using human data and iRefIndex networks. The histogram of –log10 transformed p-values are shown for
9 small molecules of Table 2, for 5 different bioinformatics tools. See the Figure 2 legend for details.
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[27]. Also, drug targets have more interactions with
other proteins on average, but fewer than essential pro-
teins [28], indicating that they are neither essential nor
peripheral. Taking it all together, as in [29], we do not as-
sume that drug targets are necessarily exhibiting signifi-
cant change in expression; they are, however, located
close to active signaling pathways and they initiate a
cascade of signaling events that ultimately generates the
observed gene expression response, as in [30].
Based on our findings, we constructed a Small Molecule
Mechanisms Database. Rather than focusing on single genes
as small molecule targets, we believe it is more useful
and gives more insight to consider groups of genes that
constitute active signaling pathways. Our database is a
collection of small molecules and their target mechanisms
in the form of active signaling pathways. Thus, we can
utilize the SMMD to search for small molecules that
have an expression signature closely matching the sig-
nature found in an experimental setup. An example of
such a search and its result is given in Figure 6.
There are some limitations to our plugin. The most
important caveat is a consequence of the noisiness andcontext-sensitivity of biological data, resulting in false
positive results due to spurious expression values or
network information. In particular, the activity of sub-
networks, pathways or single interactions is a function
of many confounding influences, ranging from obvious is-
sues such as cell-line specific effects to more hidden ones,
such as the temperature at which specific experiments
were conducted. Moreover, high throughput technology
is not all-encompassing and it may not detect all changes
in the system under investigation. Limited accuracy and
adequacy of the network structure in general is another
caveat and limitation of network analysis; certain elements
of biological systems are not readily portrayed in a net-
work context [7]. Finally, as discussed above, gene expres-
sion may not necessarily reflect protein abundance.
More specifically to our method, in the Latent Variable
framework, the network structure is represented as an
adjacency matrix and its dimension increases with the
number of genes included. Thus, calculations performed
to estimate model parameters may be computationally
demanding in case of large networks. Along these lines,
CellFateScout gives the user a choice to focus only on
nodes (genes) that she would like to investigate as
Figure 6 Screenshot of CellFateScout result. Active pathways are listed in the result table, top-left, and are given distinct colors and thicker
edges to distinguish them in the Cytoscape network view, which is rendering the network visualization in the middle. Selecting an active pathway
from the result table will select all its elements in the Cytoscape network view. There are two buttons below the result table, either to undo coloring
of a specific pathway in the network view or to delete a pathway from the result table. Below the list of active pathways, the SMMD query result is
shown in the bottom-left table, for up to 100 unique records. User selection of specific records will highlight all their pathways nodes and edges in the
network view. The user can also highlight these pathways in the Cytoscape Result Panel (right), and there the user can investigate the pathways
belonging to a small molecule record in detail. These pathways can also be highlighted in the network view.
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exploration of the pathways from all genes to all other
genes may take a long time.
Conclusions
CellFateScout is a powerful tool, easily usable as a plugin for
Cytoscape, developed to support the design of experiments
involving small molecules, with applications in cell tran-
sition research and drug repositioning. Having high
throughput data and a functional network, the user can
reveal active signaling pathways in the underlying net-
work. These active signaling pathways may be prime
candidates for more detailed modeling as in [31], to fur-
ther our understanding of small molecule perturbation
experiments. We evaluated CellFateScout on microarray
gene expression datasets with small molecules involved,
and compared results with other bioinformatics tools.
Validation showed that our plugin predicts more pre-
cisely the small molecule effects. CellFateScout evalu-
ates pathways with the Latent Variable framework that
considers the joint expression of a whole pathway,whereas most of the network-based bioinformatics tools
search for subnetworks centered around significantly
differentially expressed genes. Since the direct targets of
small molecules often do not exhibit high expression
change, methods based on differentially expressed genes
may not find genes close to target genes. Chromatin
modification drugs such as valproic acid (see Methods)
considered in our validation may be examples for this
phenomenon. They may modify chromatin by inhibition
of histone deacetylases without significant change of
histone deacetylase transcription, thus their target genes
do not necessarily occur in microarray studies as differ-
entially expressed genes or at the top of a list of these.
Our validation in human and mouse also showed that
genes with the highest expression change found with limma
are not usually close to direct targets of small molecules.
Methods
The CellFateScout tool is designed as a Cytoscape 2.8.3
[32] plugin. Cytoscape is a software for complex network
analysis and visualization implemented in Java, which can
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sets, and be extended by third party plugins. The under-
lying methodology of CellFateScout is an adaptation of
the “Latent Variable” approach [13,14] to pathway activity
estimation.
Pathway evaluation – the statistical model
We define a functional network as a gene/protein inter-
action network. Thus, the nodes in such a network rep-
resent genes and gene products (proteins), and the links
between the nodes may be regulatory (where a protein
controls the expression of a gene) or physical (where
two proteins interact). As in other work along the same
lines, gene expression data is used as a proxy for protein
expression (which is hard to obtain in a quantitative
manner), and it is assumed that gene and protein ex-
pression correlate. To simplify terminology, we therefore
refer to ‘genes’. In this study, a pathway is a linear chain
in a functional network. Such a linear chain may reflect
the backbone of a canonical pathway such as a KEGG
[33] pathway, but it may also reflect pathway crosstalk.
Per default, we investigate all linear chains in a func-
tional network, so we consider all pathway-related infor-
mation encoded by the network.
We define the activity of a pathway as the amount of
change in expression level across its nodes (genes),
which can be thought of as the information (or signal)
flow along the pathway. Pathway activity is discovered
depending on a specific formula that varies depending
on the aims of the study. Usually, change in expression
level is considered for a pair or a set of linked genes, fol-
lowing the idea that signaling includes patterns of gene
activity that are measurable by differential expression
data along the links between the genes. More specific-
ally, this measurement will be done in our case by adapt-
ing the “Latent Variable” approach, as described in the
next paragraph. We define the active signaling pathways
in a network as a set of pathways with an activity above
a specific threshold.
The Latent Variable Model [13,14] can exploit infor-
mation from an input functional network combined with
high-throughput expression data. This approach incor-
porates directly the underlying network structure into a
model with both directed and undirected edges. It as-
sumes that the expression level of each node (gene) is
based on its own expression and on the influence of the
expression of other genes. The contribution of a gene g
to its expression level is called a latent variable, and is
modeled as a normally distributed random variable. On
the other hand, the influence of other genes on the ex-
pression level of g is calculated from the expression level
of the genes linked to g, considering the incoming edge
weights. The Latent Variable Model can be represented
as a Mixed Linear Model. Then, the fixed effects ofthe latent variables can be tested. In our adaptation, we
consider pathways in the form of linear chains. The
authors of [14] then consider a statistical test for each
specific subnetwork, where the null hypothesis is as-
suming that there is no change in time of a gene’s
self-contribution to its expression level and there is no
change of its influence to other genes in this subnet-
work. The testing is done using the Wald test statistic
that under the null hypothesis follows approximately a
t-distribution. Using this framework, [14] developed a
general inference procedure that can be used to identify
active subnetworks in complex experiments over time.
This framework requires extensive adjustment of the
statistical analysis for every new application [34]. In our
case, the adjustment was done as follows. To be simple
and applicable to experiments involving two conditions,
e.g. before and after an intervention, or case and con-
trol, we simplified the Latent Variable Model framework
for two conditions and an underlying network, the struc-
ture of which does not change over time. In general, this
simplified framework allows researchers to investigate
the activity of any kind of subnetwork of interest, but
the scope of CellFateScout is the identification of active
pathways in the form of a linear chain, simplifying and
speeding up the analyses. In particular, with our adapta-
tion of the method we determine significance estimates
(p-values) for the activation status of all pathway chains
that we choose to explore, rank them based on the
p-value and highlight them in the network. The same
approach is also utilized for the small molecule data-
base construction.
Validation methodology
We selected datasets of small molecules with corre-
sponding gene expression and functional network data
and developed a validation scheme as described below that
estimates the closeness between known targets of the small
molecules and the active subnetworks/pathways (or corre-
sponding gene sets) found by the bioinformatics tools.
For our validation effort, we collected publicly avail-
able microarray experiments for two organisms, mouse
and human, where only one small molecule is investigated
per microarray. Target genes of these small molecules
had to be included in the STITCH database version 3.1,
a chemical-protein interactions resource [21]. There, every
interaction between a small molecule and a gene/protein
has a confidence score of at most 1. In order to consider
only small molecules with a high likelihood that there
exist correctly curated target genes, we used a confidence
threshold of 0.9. Finally, we required microarray data
to meet the criterion of having replicates for case and
for control.
For mouse, we investigated small molecules that are
known to modulate embryonic stem cell fate and somatic
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http://www.biosignaling.com/content/11/1/85cell reprogramming. Zhang collected these in a review
[35]; out of the 39 listed there, 12 have high confidence
targets in STITCH and feature experiments with repli-
cates in the Gene Expression Omnibus (GEO) repository
as of January 2013 [36]. From this set of small molecules
we do not consider retinoic acid due to its high number of
84 target genes, and we therefore investigated 11 small
molecules. A summary of our data is presented in Table 1.
We imported normalized microarray expression sets from
the GEO database into the R statistical computing and
graphics environment [37] using the Bioconductor pack-
age GEOquery [38]. These expression sets can be directly
passed on to Cytoscape and used with CellFateScout.
Other tools required additional steps in data preparation.
For jActiveModules, we had to assign a p-value from dif-
ferential expression analysis to the genes and for this we
used the R limma package. KeyPathwayMiner requires a
selection of differentially expressed genes from the net-
work. Here, we followed the original manuscript and
processed the data as described there.
For human, we selected small molecules applied in
chromatin-modification therapeutic studies in cancer
and a summary of such studies (clinical trials) is assem-
bled in Mai [50] in the supplement therein. We applied
the same criteria as for mouse to narrow down our set















Dorsomorphin 6 677043, 677044 677041, 677042















SB203580 20 37115, 37116 37106, 37107




SU5402 2 400317, 400318,
400319
400305, 400306, 400307
Trichostatin A 12 8898, 8902 8900, 8904
U0126 13 377044, 377045,
377046
376950, 376951, 376952
Valproic Acid 19 234805, 234806,
234807, 234808
234794, 234795, 234796
234797target genes in STITCH. Then, we intersected them with
all small molecules that were used in the Connectivity
Map. This intersection is meaningful because both the
clinical trials of Mai and the Connectivity Map data are
based on cancer cell lines. We further focused only on
microarrays that were performed with the breast cancer
epithelial cell line MCF7. Finally, from the 14 drugs sur-
viving all filters described, we omitted those with a high
number of more than 100 human target genes. For the
resulting 10 small molecules, the corresponding micro-
arrays and their controls were normalized (see SMMD
construction, above), processed as for mouse (see above)
and passed for validation as described below. A summary
of the human data can be found in Table 2.
Focusing on protein-protein and protein-gene interac-
tions to identify active signaling pathways from expression
data (see also [8,26,51-54]), we used two distinct database
repositories to construct functional networks for both spe-
cies, mouse and human, setting the appropriate species as a
database retrieval parameter. In a first approach, we uti-
lized information from the STRING database (version 9.0)
[55]. Their website allows to import and construct pro-
tein/gene interaction and regulation networks for up to
2000 genes, and thus, for each small molecule/microarray
experiment, we based our network construction upon the







, [39] 189/162/2 128/97/1
[40] 258/202/6 161/131/5
, [41] 338/445/1 246/223/1











, [49] 332/614/17 -
Table 2 Human data used for validation
Human
Small molecule Number of targets
in STITCH






Azacitidine 8 0.0000164 HT_HG-U133A 1539/4029/8 1559/5804/7
Doxorubicin 48 0.0000068 HT_HG-U133A 1504/3937/44 1574/5896/45
Etoposide 41 0.0000068 HT_HG-U133A 1510/4171/37 1540/5514/39
Hydralazine 3 0.0000204 HT_HG-U133A 1468/2977/3 1372/3633/3
Lithocholic Acid 59 0.0000106 HT_HG-U133A 1414/2745/59 1282/2649/54
Methylprednisolone 6 0.0000106 HT_HG-U133A 1411/3239/5 1389/3653/5
Prednisone 1 0.0000112 HT_HG-U133A 1433/2988/1 -
Tamoxifen 56 0.000007 HT_HG-U133A 1468/3400/56 1505/4969/49
Valproic Acid 20 0.001 HT_HG-U133A 1386/2870/19 1451/4382/17
Vorinostat 22 0.00001 HT_HG-U133A 1505/4302/22 1580/6135/22
Siatkowski et al. Cell Communication and Signaling 2013, 11:85 Page 12 of 16
http://www.biosignaling.com/content/11/1/85GEO2R, a GEO tool that in turn employs the limma R
package. We then set a high confidence STRING score
threshold of 0.9 for filtering out unreliable links and de-
leted from the network all genes that are not linked to
any other gene. In a second approach, we considered
the same top 2000 genes, but we used functional network
information taken from the iRefIndex database version
9.0 [20]. We considered networks from both repositor-
ies as undirected. Summaries of our data assembly and
network constructions are also given in Tables 1 and 2.
(For two small molecules in the mouse data, SB431542
and Valproic Acid, and for Prednisone in the human
data, target genes are not found in the complete mouse
or human iRefIndex network, thus it is not possible to
conduct the validation for these small molecules in case
of iRefIndex).
We defined the neighborhood of a small molecule within
a network as its target genes and their neighbors, up to a
specific distance. We expected the genes in the neighbor-
hood to be affected by the small molecule, that is, to fea-
ture a change in their expression. Our validation is thus
based on the question: are the active pathways we find
close to the known targets? In other words, in how far
does the neighborhood of the small molecule, based on its
targets, coincide with the pathways it is supposed to ac-
tivate, based on the expression data of the experiment
measuring its effects?
All of the bioinformatics tools we compare represented
different ways to identify such small molecule effects, by
gene-wise independent testing, highlighting links or iden-
tifying active subnetworks. We used these tools together
with expression experiments and corresponding networks
to compare their accuracy in identifying relevant pathway
activity patterns, as follows. We ran our plugin on all data-
sets we collected (Tables 1 and 2) and performed anexhaustive search investigating every pathway of size up to
6, consisting of 7 genes connected by 6 links; 6 is the first
integer greater than the right-hand side of the 95% con-
fidence interval for the average path length of all con-
structed networks, that is (4.42, 5.22). Each exhaustive
search resulted in a listing of the 10 most active path-
ways, based on the gene expression data of the micro-
array and the corresponding network. Then, we ran other
tools with default settings on the same datasets and col-
lected the results top-down (best results first) to obtain
(almost) the same number of genes as we did using
CellFateScout. To facilitate comparison of the gene lists
from limma, links (gene pairs) from ExprEssence, active
pathways from CellFateScout, and active subnetworks
from jActiveModules and KeyPathwayMiner, we treated
all results as sets of individual genes embedded in a net-
work. In order to analyze the proximity of these gene
sets to the small molecule targets as defined by STITCH,
we defined a formula for the distance between a gene and
a small molecule in terms of a network, and, more
generally, between a set of genes and a small molecule
(see below). Small molecule target genes and their neigh-
borhoods often do not occur in the network constructed
out of the 2000 most differentially expressed genes, since
signaling is not always reflected by transcriptional change,
but also e.g. by phosphorylation of the protein product.
For this reason we calculated the distance of a gene to a
small molecule considering the whole network of inter-
actions from STRING (with confidence score at least
0.9) or from iRefIndex. The distances between the tar-
gets and the genes found by the bioinformatics tools can
be found in Additional file 1 for mouse and Additional
file 2 for human.
The distance of a single gene to a small molecule is
the shortest distance of this gene to its closest small
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http://www.biosignaling.com/content/11/1/85molecule target in the network. Further, we introduced a
weighting function so that a weight is assigned to each
distance based on the size of the neighborhood of the
small molecule. This weight will be high if the gene is
near a small molecule and the number of genes of the
same, or smaller, distance to this molecule is low. With
this weighting we give strong weight to the distances
of genes proximal or coinciding with target genes. The
weight of distance i is








Here, ni indicates the number of genes in the network
of distance i or less (with respect to the gene in question)
and N the number of all nodes in the network. Thus,
the weighting function is monotonically decreasing with
respect to i, when N is fixed. A visualization of this
approach is presented in Figure 7. Next, the distance
of a set of genes to a small molecule is defined as the
weighted mean of the individual distances. This gives
a score for the distances of a set of genes and compensates
that some bioinformatics tools return a variable number
of genes; with more genes in a gene set, the expected
number of hits (genes near targets) is also increasing.
Finally, we challenged all bioinformatics tools against
results from randomization. Thus, we applied a boot-
strapping technique to create a sample distribution by1 1
Target
222 22
3 3 3 3 3 3 3 333 3 3 3 3
Figure 7 Visualization of the weighting function used in our validation
or coinciding with target genes. A weight is assigned to a gene based on its
small molecule. In this toy example, we have network nodes of distance 0 (ta
number of genes of distance i or less to these targets. The weight of a pathw
function and e.g. for a node of distance 2 in this toy example, the weight is 0generating 10000 random gene sets of the same size as
the average of the resulting pathways and calculating the
distance scores of these random sets to the small molecule
under investigation. Using this random sample we cal-
culated one-sided p-values. These p-values are easier to
interpret, more meaningful and easier to compare than
weighted mean distances: They describe how much bet-
ter the results taken from the bioinformatics tools are,
compared to “pathways” based on selecting genes ran-
domly, and they are not affected by topological bias in
the network.
As a result of our validation, we obtained p-values,
measuring our improvement over chance findings, i.e. how
much closer to the known targets are the active pathways
we find, compared to random pathways, and how sig-
nificant is this difference? We obtained the same kind of
p-values for the other bioinformatics tools. In order
to visualize the validation results, we transformed the
resulting p-values from the randomization test, taking
the − log10(p − value).
CellFateScout input
The plugin requires a functional network and at least
two high-throughput datasets (differentially describing two
conditions) imported into Cytoscape. The network con-
sists of nodes and edges. As described, with respect to
the nodes, we do not distinguish between genes and pro-









3 3 3 3 3 3
approach. Using the weighting function promotes gene sets proximal
distance to the small molecules and the size of the neighborhood of the
rgets), 1, 2 and 3 to the small molecules targets and ni represents the
ay gene (colored in yellow) is calculated based on the weighting
.860.
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http://www.biosignaling.com/content/11/1/85between gene products (proteins) as well as regulatory
interactions between genes and proteins. Both kinds of
interactions are called links. The former are usually undir-
ected, while the latter may be directed (stimulations, inhibi-
tions). Links may be weighted by their strength, which may
be measured experimentally. By default, the network is
treated as undirected and unweighted. Nevertheless, the
user can select edges and define their directionality and
assign weights. The expression values must be imported
as node attributes and due to the statistical model utilized,
only data with at least two replicates per condition can be
processed.
Interface of the CellFateScout plugin and output
The CellFateScout user interface is implemented in a way
that it is easy to grasp for non-computer scientists, but
still functional and comprehensive. A tutorial is avail-
able at http://sourceforge.net/projects/cellfatescout and
as Additional file 5. Before the user starts the plugin, a
Cytoscape session with a valid network and expression
data must be uploaded. In a first step, the user may ex-
plicitly define edge directionalities. When there is add-
itional information about the links, CellFateScout also
allows assigning weights to these. Thus, the user can
control how pathways will be investigated and which
links have high priority.
Complex networks feature a high fraction of all pos-
sible links and analyzing all resulting pathways is very
often neither possible nor necessary. Therefore, the plu-
gin lets the user decide how to explore the network, by
marking the nodes or edges that correspond to the start
and to the end of the pathways to be explored. The user
tags these nodes or edges in the Cytoscape network view.
Additionally, CellFateScout allows selecting the entire
neighborhood of a specified node. An edge is considered
as the set of its two nodes. These multiple ways of node
and edge selection give the user the opportunity to ex-
ploit the network in a way that suits best. In the minim-
alist scenario the user can select a single node for the
start and for the end, whereas selecting all nodes as start
as well as end points will trigger an exhaustive exploration.
Finally, the user selects Cytoscape node attributes repre-
senting two conditions (e.g. case and control) from a high-
throughput experiment. After computation, the most active
signaling pathways with lowest p-values in the input Cytos-
cape network are shown in a table and marked by colors
in the table and the Cytoscape network view. We also
provide adjusted p-values after multiple testing correc-
tion using the Benjamini-Hochberg procedure [56]. The
resulting pathways are sorted in the table from most to
least significant (from low to high p-value), and delin-
eated by color. If the resulting pathways have overlap-
ping edges in the Cytoscape network view, colors are given
based on rank. To keep the view simple and readable, bydefault we only consider the top ten pathways with top
ranks. Selection of pathways in the result table will
select all their elements, nodes and edges, in the Cytos-
cape network view. We also provide features that allow
the user to delete pathways from the results table. When a
pathway is deleted from the results table, the next signifi-
cant pathway in the ranking that was not appearing in the
table will be shown and displayed in the network view.
Once we know the activity pattern of the signaling path-
ways in the network, we can perform an automatic simi-
larity search in the Small Molecule Mechanisms Database
(SMMD) for matching pathways based on Connectivity
Map data. Only user-selected active pathways from the re-
sults table will be queried for matching pathways. The
matching pathways from the SMMD are associated with
small molecules, each with information about the small
molecule concentration, the cell line with which the ex-
periment was conducted and the microarray platform
used. (In each SMMD record, a small molecule and its
associated information are connected to the pathways
being activated). The matching database pathways are
sorted based on a similarity score (see above) and up to
100 unique records with database pathways having the
best similarity scores are shown. User selection of spe-
cific records will highlight, for all matching pathways,
their nodes and edges in the Cytoscape network view.
To investigate the pathways belonging to a specific rec-
ord, the user can obtain their description in a Cytoscape
Results Panel. In turn, the described pathways can be
highlighted one-by-one in the Cytoscape network view
by selecting them in the Results Panel. Since not all nodes
or edges of a pathway belonging to a record have to be
present in the original network for which the matching
pathway was calculated, only some elements may be
highlighted in the Cytoscape network view. An example
view of a Cytoscape session while using CellFateScout is
presented in Figure 6.Additional files
Additional files 1: Mouse validation summary. Table that summarizes
detailed results from mouse validation including weighted means distances,
p-values, and the number of genes at a certain distance to the small molecules.
Additional files 2: Human validation summary. Table that
summarizes detailed results from human validation including weighted
means distances, p-values, and the number of genes at a certain distance
to the small molecules.
Additional files 3: Small Molecule Mechanisms Database records.
Summary of all small molecules from Connectivity Map included in the
SMMD, including their respective concentration, cell line and Affymetrix
microarray platform.
Additional files 4: Small Molecule Mechanisms Database. The database
is constructed with ObjectDB (www.objectdb.com), a Java oriented database
management system. Content of this file can be viewed with the ObjectDB
Explorer tool, which is a part of the ObjectDB project. This file is also available
at http://sourceforge.net/projects/cellfatescout.
Siatkowski et al. Cell Communication and Signaling 2013, 11:85 Page 15 of 16
http://www.biosignaling.com/content/11/1/85Additional files 5: CellFateScout step-by-step tutorial for a case
study. Tutorial that presents how CellFateScout can be utilized on an
expression dataset. For this, we used the public microarray expression
dataset available at GEO [36] under accession number GSE37896 [57].
This study is measuring gene expression change in iPS induction by
lentiviral Yamanaka factors applied to adipose stem cells.
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